Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 2902-2914
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2902
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2902
Adagrasib (n = 21)[57] | Sotorasib (n = 38)[63] | |
Objective response rate (95%CI) | 33 (15-57) | 21 (10-37) |
Disease control rate | 81 | 84 |
Median duration of response (months) | NA | 5.7 (1.6-non evaluable) |
Progression-free survival (months) (95%CI) | 5.4 (3.9-8.2) | 4.0 (2.8-5.6) |
Overall survival (months) (95%CI) | 8.0 (5.2-11.8) | 6.9 (5.0-9.1) |
Grade 3-4 toxicities | 27 | 16 |
Dose reduction | 40 (solid tumours) | 13 |
Discontinuation for toxicity | 0 | 0 |
- Citation: Boileve A, Smolenschi C, Lambert A, Boige V, Tarabay A, Valery M, Fuerea A, Pudlarz T, Conroy T, Hollebecque A, Ducreux M. Role of molecular biology in the management of pancreatic cancer. World J Gastrointest Oncol 2024; 16(7): 2902-2914
- URL: https://www.wjgnet.com/1948-5204/full/v16/i7/2902.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.2902